Biomarker profiling to determine clinical impact of microRNAs in cognitive disorders
Abstract Alzheimer’s disease (AD) and post-stroke cognitive impairment (PSCI) are the leading causes of progressive dementia related to neurodegenerative and cerebrovascular injuries in elderly populations. Despite decades of research, patients with these conditions still lack minimally invasive, lo...
Main Authors: | Weijie Zhai, Meng Zhao, Chunxiao Wei, Guimei Zhang, Yiming Qi, Anguo Zhao, Li Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-04-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-58882-2 |
Similar Items
-
Circulating microRNAs in Alzheimer’s disease: the search for novel biomarkers
by: Veronique eDorval, et al.
Published: (2013-08-01) -
Plasma fibrinogen as a potential biomarker of cognitive impairment after acute ischemic stroke
by: Chunxiao Wei, et al.
Published: (2024-12-01) -
A microRNA signature that correlates with cognition and is a target against cognitive decline
by: Md Rezaul Islam, et al.
Published: (2021-10-01) -
Mutual Interaction of Clinical Factors and Specific microRNAs to Predict Mild Cognitive Impairment in Patients Receiving Hemodialysis
by: Jin-Bor Chen, et al.
Published: (2020-10-01) -
Cognitive dysfunction associated with COVID-19: Prognostic role of circulating biomarkers and microRNAs
by: Marissa Alvarez, et al.
Published: (2022-10-01)